Frontier Bio

Frontier Bio is a biotechnology company that specializes in advanced tissue engineering and biofabrication. The company develops lab-grown human tissue models designed to serve as high-fidelity alternatives to preclinical animal testing. These models, which include proprietary platforms like NeuroTraX for blood-brain barrier research and RESPIRE for lung tissue analysis, help researchers investigate drug transport, toxicity, and disease mechanisms in a human-relevant environment. Additionally, Frontier Bio is developing regenerative vascular grafts composed of a bioresorbable scaffold seeded with a patient's own stem cells, intended to transform into a natural, living blood vessel following implantation.

These technologies aim to address significant healthcare challenges, including the global organ shortage and the limitations of current synthetic vascular grafts, which often suffer from high failure rates or invasive harvesting requirements. By commercializing tissue models for research, the company generates revenue to support its long-term clinical development programs, including efforts to reach first-in-human trials. Their work is intended to improve the accuracy of drug development processes and provide durable, patient-specific solutions that reduce the need for immune-suppressing therapies and invasive surgical procedures.